10 reasons why perindopril should be preferential drug in treatment of hypertension Review article
Article Sidebar
Published:
Mar 31, 2017
Keywords:
perindopril, angiotensin, hypertension
Main Article Content
Abstract
Angiotensin-converting enzyme (ACE) inhibitors are a heterogeneous class, varying in pharmacologic properties, which have different therapeutic impacts on patient profiles, including lipophilicity, tissue-ACE binding, duration of action, half-life, and increased bradykinin availability. Among the ACE inhibitor class, the agent perindopril, in particular, has pleiotropic effects that are not equally shared by other ACE inhibitors, including bradykinin site selectivity and subsequent enhancement of nitric oxide and inhibition of endothelial cell apoptosis.
Downloads
Download data is not yet available.
Article Details
How to Cite
Pordzik , J., & Postuła , M. (2017). 10 reasons why perindopril should be preferential drug in treatment of hypertension. Cardiology in Practice, 11(1), 8-11. Retrieved from https://journalsmededu.pl/index.php/kwp/article/view/1254
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Unger T., Ganten D., Lang R.E.: Tissue converting enzyme and cardiovascular actions of converting enzyme inhibitors. J. Cardiovasc. Pharmacol. 1986; 8(supl. 10): S75-S81.
2. Zhuo J.L., Mendelsohn F.A., Ohishi M.: Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension 2002; 39(2 pt 2): 634-638.
3. Ferrari R.: Preserving bradykinin or blocking angiotensin II: the cardiovascular dilemma. Dialogues Cardiovasc. Med. 2004; 9(2): 71-89.
4. Morgan T., Anderson A.: Clinical efficacy of perindopril in hypertension. Clin. Exp. Pharmacol. Physiol. Suppl. 1992; 19: 61-65.
5. Farnsworth A.: Angiotensin-converting enzyme inhibitors in heart failure: target dose prescription in elderly patients. Age Ageing. 1998; 27(5): 653-654.
6. Ceconi C., Francolini G., Olivares A. et al.: Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur. J. Pharmacol. 2007; 577(1-3): 1-6.
7. Watanabe K., Saito Y., Ma M. et al.: Comparative effects of perindopril with enalapril in rats with dilated cardiomyopathy. J. Cardiovasc. Pharm. 2003; 42(supl. 1): S105-S109.
8. Vítovec J., Spinar J.: First-dose hypotension after angiotensin-converting enzyme (ACE) inhibitors in chronic heart failure: a comparison of enalapril and perindopril. Slovak Investigator Group. Eur. J. Heart Fail. 2000; 2(3): 299-304.
9. MacFadyen R.J., Lees K.R., Reid J.L.: Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study. Br. Heart J. 1991; 66(3): 206-211.
10. Cushman D.W., Cheung H.S.: Concentrations of angiotensin-converting enzyme in tissues of the rat. Biochim. Biophys. Acta Oct. 1971; 250(1): 261-265.
11. Dzau V.J., Bernstein K., Celermajer D. et al.: The relevance of tissue angiotensin converting enzyme: manifestations in mechanistic and endpoint data. Am. J. Cardiol. 2001; 88(9A): 1L-20L.
12. Fabris B., Chen B.Z., Pupic V. et al.: Inhibition of angiotensin-converting enzyme (ACE) in plasma and tissue. J. Cardiovasc. Pharmacol. 1990; 15(supl. 2): S6-S13.
13. Ranadive S.A., Chen A.X., Serajuddin A.T.: Relative lipophilicities and structural pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors. Pharm. Res. Nov. 1992; 9(11): 1480-1486.
14. Johnston C.I.: Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. Hypertension 1994; 23(2): 258-268.
15. Burris J.F.: The expanding role of angiotensin converting enzyme inhibitors in the management of hypertension. J. Clin. Pharmacol. 1995; 35(4): 337-342.
16. Lala A., McLaughlin M.A.: Do ACE inhibitors all provide the same outcomes benefits in high-risk cardiovascular patients? Curr. Hypertens. Rep. 2008; 10(4): 286-292.
17. Ceconi C., Francolini G., Bastianon D. et al.: Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc. Drugs. Ther. 2007; 21(6): 423-429.
18. Watanabe K., Saito Y., Ma M. et al.: Comparative effects of perindopril with enalapril in rats with dilated cardiomyopathy. J. Cardiovasc. Pharm. 2003; 42(supl. 1): S105-S109.
19. Pilote L., Abrahamowicz M., Rodrigues E. et al.: Mortality rates in elderly patients who take different angiotensin converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann. Int. Med. 2004; 141(2): 102-112.
20. Comini L., Bachetti T., Cargnoni A. et al.: Therapeutic modulation of the nitric oxide: all ace inhibitors are not equivalent. Pharmacological Res. 2007; 56(1): 42-48.
21. Krysiak R., Sierant M., Marek B., Okopien B.: The effect of perindopril and enalapril on plasma resistin levels in normotensive patients with coronary heart disease. Endokrynologia Polska 2010; 61(6): 683-690.
22. Krysiak R., Okopien B.: Pleiotropic effects of angiotensin-converting enzyme inhibitors in normotensive patients with coronary artery disease. Pharmacol. Rep. 2008; 60(4): 514-523.
23. Brugts J.J., Ninomiya T., Boersma E. et al.: The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur. Heart J. 2009; 30(11): 1385-1394.
24. Pilote L., Abrahamowicz M., Eisenberg M. et al.: Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. CMAJ 2008; 178(10): 1303-1311.
25. Alderman C.P.: Adverse effects of the angiotensin-converting enzyme inhibitors. Ann. Pharmacother. 1996; 30(1): 55-61.
26. Fox K.M.: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003; 362(9386): 782-788.
27. Yusuf S., Sleight P., Pogue J. et al.: Effects of an angiotensin-converting enzyme inhibitor, ramipryl, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 2000; 342(3): 145-153.
28. PROGRESS Collaborative Group. Randomised trial of a perindopril based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358(9287): 1033-1041.
29. Ceconi C., Fox K.M., Remme W.J. et al.: ACE-inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc. Res. 2007; 73(1): 237-246.
30. Cargnoni A., Comini L., Bernocchi P. et al.: Role of bradykinin and eNOS in the anti-ischaemic effect of trandolapril. British J. Pharm. 2001; 133(1): 145-153.
31. du Toit E.F., Genade S., Carlini S. et al.: Efficacy of ischaemic preconditioning in the eNOS overexpressed working mouse heart model. Eur. J. Pharmacol. 2007; 556(1-3): 115-120.
32. Cleland J.G., Tendera M., Adamus J. et al.: The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur. Heart J. 2006; 27: 2338-2345.
33. Masuell M., Brusca G., Pardo A. et al.: ACE inhibitors in heart failure – switching from enalapril to perindopril. Curr. Med. Res. Opin. 2002; 18(5): 296-302.
2. Zhuo J.L., Mendelsohn F.A., Ohishi M.: Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension 2002; 39(2 pt 2): 634-638.
3. Ferrari R.: Preserving bradykinin or blocking angiotensin II: the cardiovascular dilemma. Dialogues Cardiovasc. Med. 2004; 9(2): 71-89.
4. Morgan T., Anderson A.: Clinical efficacy of perindopril in hypertension. Clin. Exp. Pharmacol. Physiol. Suppl. 1992; 19: 61-65.
5. Farnsworth A.: Angiotensin-converting enzyme inhibitors in heart failure: target dose prescription in elderly patients. Age Ageing. 1998; 27(5): 653-654.
6. Ceconi C., Francolini G., Olivares A. et al.: Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur. J. Pharmacol. 2007; 577(1-3): 1-6.
7. Watanabe K., Saito Y., Ma M. et al.: Comparative effects of perindopril with enalapril in rats with dilated cardiomyopathy. J. Cardiovasc. Pharm. 2003; 42(supl. 1): S105-S109.
8. Vítovec J., Spinar J.: First-dose hypotension after angiotensin-converting enzyme (ACE) inhibitors in chronic heart failure: a comparison of enalapril and perindopril. Slovak Investigator Group. Eur. J. Heart Fail. 2000; 2(3): 299-304.
9. MacFadyen R.J., Lees K.R., Reid J.L.: Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study. Br. Heart J. 1991; 66(3): 206-211.
10. Cushman D.W., Cheung H.S.: Concentrations of angiotensin-converting enzyme in tissues of the rat. Biochim. Biophys. Acta Oct. 1971; 250(1): 261-265.
11. Dzau V.J., Bernstein K., Celermajer D. et al.: The relevance of tissue angiotensin converting enzyme: manifestations in mechanistic and endpoint data. Am. J. Cardiol. 2001; 88(9A): 1L-20L.
12. Fabris B., Chen B.Z., Pupic V. et al.: Inhibition of angiotensin-converting enzyme (ACE) in plasma and tissue. J. Cardiovasc. Pharmacol. 1990; 15(supl. 2): S6-S13.
13. Ranadive S.A., Chen A.X., Serajuddin A.T.: Relative lipophilicities and structural pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors. Pharm. Res. Nov. 1992; 9(11): 1480-1486.
14. Johnston C.I.: Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. Hypertension 1994; 23(2): 258-268.
15. Burris J.F.: The expanding role of angiotensin converting enzyme inhibitors in the management of hypertension. J. Clin. Pharmacol. 1995; 35(4): 337-342.
16. Lala A., McLaughlin M.A.: Do ACE inhibitors all provide the same outcomes benefits in high-risk cardiovascular patients? Curr. Hypertens. Rep. 2008; 10(4): 286-292.
17. Ceconi C., Francolini G., Bastianon D. et al.: Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc. Drugs. Ther. 2007; 21(6): 423-429.
18. Watanabe K., Saito Y., Ma M. et al.: Comparative effects of perindopril with enalapril in rats with dilated cardiomyopathy. J. Cardiovasc. Pharm. 2003; 42(supl. 1): S105-S109.
19. Pilote L., Abrahamowicz M., Rodrigues E. et al.: Mortality rates in elderly patients who take different angiotensin converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann. Int. Med. 2004; 141(2): 102-112.
20. Comini L., Bachetti T., Cargnoni A. et al.: Therapeutic modulation of the nitric oxide: all ace inhibitors are not equivalent. Pharmacological Res. 2007; 56(1): 42-48.
21. Krysiak R., Sierant M., Marek B., Okopien B.: The effect of perindopril and enalapril on plasma resistin levels in normotensive patients with coronary heart disease. Endokrynologia Polska 2010; 61(6): 683-690.
22. Krysiak R., Okopien B.: Pleiotropic effects of angiotensin-converting enzyme inhibitors in normotensive patients with coronary artery disease. Pharmacol. Rep. 2008; 60(4): 514-523.
23. Brugts J.J., Ninomiya T., Boersma E. et al.: The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur. Heart J. 2009; 30(11): 1385-1394.
24. Pilote L., Abrahamowicz M., Eisenberg M. et al.: Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. CMAJ 2008; 178(10): 1303-1311.
25. Alderman C.P.: Adverse effects of the angiotensin-converting enzyme inhibitors. Ann. Pharmacother. 1996; 30(1): 55-61.
26. Fox K.M.: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003; 362(9386): 782-788.
27. Yusuf S., Sleight P., Pogue J. et al.: Effects of an angiotensin-converting enzyme inhibitor, ramipryl, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 2000; 342(3): 145-153.
28. PROGRESS Collaborative Group. Randomised trial of a perindopril based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358(9287): 1033-1041.
29. Ceconi C., Fox K.M., Remme W.J. et al.: ACE-inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc. Res. 2007; 73(1): 237-246.
30. Cargnoni A., Comini L., Bernocchi P. et al.: Role of bradykinin and eNOS in the anti-ischaemic effect of trandolapril. British J. Pharm. 2001; 133(1): 145-153.
31. du Toit E.F., Genade S., Carlini S. et al.: Efficacy of ischaemic preconditioning in the eNOS overexpressed working mouse heart model. Eur. J. Pharmacol. 2007; 556(1-3): 115-120.
32. Cleland J.G., Tendera M., Adamus J. et al.: The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur. Heart J. 2006; 27: 2338-2345.
33. Masuell M., Brusca G., Pardo A. et al.: ACE inhibitors in heart failure – switching from enalapril to perindopril. Curr. Med. Res. Opin. 2002; 18(5): 296-302.